Lighting the way in TBI
ArcheOptix Biomedical, Inc. is a privately-held, medical device company that has developed technologies to rapidly and accurately assess the severity of Traumatic Brain Injury (TBI). Our unique and novel approach to Near Infrared Spectroscopy (NIRS), has allowed us to take an old idea and create something that is now medically viable. By introducing motion to NIRS, we offer a revolutionary advance on previous technologies' ability to detect and image intra-cranial bleeds and concussion.
Our devices are non-invasive, non-ionizing, portable and very easy to use. The assessment procedure takes 1 – 3 minutes. Our devices will allow for the rapid and accurate assessment as to the severity of TBI, helping the person at the point of injury determine the need for an immediate CT scan.
ArcheOptix Biomedical Inc. is an ISO-certified company (ISO 13485:2003 with CMDCAS).
Founder and CEO, Sav Stratis, is an entrepreneur with operations, sales and marketing expertise, primarily in the chemical and pharmaceutical industry . Sav has over 20 years of hands-on experience dealing with regulatory bodies (Health Canada, FDA, and EPA), suppliers, distributors, and buyers in foreign countries (China, India, EU, USA).
Dr. Jason Riley, lead inventor of the technology, is an expert with more than a decade of experience in Near Infrared biophotonics. Jason has a Bachelor’s in electronic engineering, a Master’s in research and a PhD from University College London. Jason continued his research career at the National Institutes of Health, Bethesda, USA, before joining ArcheOptix.
Theo Mavraganis, VP of Engineering, has over 20 years’ experience in R&D in hardware design, software design, and in R&D management. Theo was among the founding members of Newbridge Networks Corp. and was at Alcatel after the acquisition. Theo has a Bachelor's degree in Electrical/Computer Engineering and Applied Science from Queen's University.